Pharmafile Logo

News and Press Releases

PACE launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health

1 October 2025 -- Alderley Park, UK -- To stay ahead of the escalating antibiotic resistance crisis, we need bold thinking and transformative innovation. According to the World Health Organization...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025

PACE

Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulatorfor the Treatment of Cystic Fibrosis

Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Vertex Pharmaceuticals

Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis

Ingelheim, Germany – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931,...

Category: Biotechnology
Posted: February 24, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate

£500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis Programme delivered by CF AMR Syndicate offers cross-sector collaboration and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 21, 2025

Glox Therapeutics
info@gloxtherapeutics.com
11 The Square University Of Glasgow University Avenue Glasgow G12 8QQ

ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...

Category: BioManufacturing
Posted: September 9, 2024

ERS Genomics
8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland

Destiny Pharma initiates research to explore XF drug potential for CF

Study to investigate the potential of XF-73 to treat MRSA infection in people with cystic fibrosis 14 August 2024 -- Brighton, UK -- Destiny Pharma, a clinical stage biotechnology company...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 14, 2024

Destiny Pharma
pressoffice@destinypharma.com
Destiny Pharma plc, Sussex Innovation Centre, Science Park Square, Brighton, BN1 9SB UK

Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director

Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...

Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024

Enterprise Therapeutics
info@enterprisetherapeutics.com
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024

Enterprise Therapeutics
info@enterprisetherapeutics.com
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK

New £30m Initiative to Address Global Threat by Accelerating the Pace of Antimicrobial Innovation

Pioneering partnership to drive development of new tests and treatments to tackle deadly antimicrobial resistance, which could otherwise kill 10 million a year by 2050 19 October 2023 -- Swindon,...

Category: Other
Posted: October 19, 2023

Innovate UK
Innovate UK Polaris House, North Star Avenue, Swindon, SN2 1FL